Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 13Other hematologic neoplasm 9Lymphoid 6Thoracic 4Sarcoma 3Tumor-Agnostic 1Plasma cell 1Myeloid 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Stomach Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Trastuzumab 728Paclitaxel 694Cyclophosphamide 647Docetaxel 559Capecitabine 485Letrozole 437Fulvestrant 398Carboplatin 397Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 272exemestane 258Epirubicin 251Radiotherapy 239pertuzumab 237palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 151Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
devimistat × Breast × Clear all
NCT01832857 2016-12-29

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Cornerstone Pharmaceuticals

Phase 2 Terminated
7 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡